3,667 results match your criteria Fallopian Tube Disorders


The Gynecologic Health Consequences of Chlamydia trachomatis Infection in Military Servicewomen.

Semin Reprod Med 2018 Nov 19;36(6):340-350. Epub 2019 Apr 19.

Department of Clinical Investigation, Madigan Army Medical Center, Tacoma, Washington.

is the most common sexually transmitted bacterial infection in the United States. Within the U.S. Read More

View Article

Download full-text PDF

Source
http://www.thieme-connect.de/DOI/DOI?10.1055/s-0039-1678752
Publisher Site
http://dx.doi.org/10.1055/s-0039-1678752DOI Listing
November 2018
5 Reads

A patient from Zhejiang, China, with synchronous mucinous metaplasia and neoplasms of the female genital tract: A case report.

J Obstet Gynaecol Res 2019 Apr 16. Epub 2019 Apr 16.

Department of Gynecology, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, China.

Synchronous mucinous metaplasia and neoplasms of the female genital tract (SMMN-FGT) is a rare disease reported by a few scholars without the consensus of diagnosis and treatment. Here we will report a 57-year-old female patient from Zhejiang China who suffered from this disease. She came to our hospital because of a large amount of vaginal discharge. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jog.13959DOI Listing
April 2019
2 Reads

[Infertility caused by salpingitis treated based on theory of kidney deficiency and blood stasis].

Zhongguo Zhong Yao Za Zhi 2019 Mar;44(6):1099-1103

Xiyuan Hospital,China Academy of Chinese Medical Sciences Beijing 100091,China.

Infertility caused by salpingitis is one of the main causes of secondary infertility in women. In recent years,the incidence has been increasing year by year. Modern medicine believes that this disease is a complication due to incomplete or delayed treatment of acute and chronic salpingitis,with no satisfactory drug therapy at present. Read More

View Article

Download full-text PDF

Source
http://www.cnki.net/kcms/doi/10.19540/j.cnki.cjcmm.20181225.
Publisher Site
http://dx.doi.org/10.19540/j.cnki.cjcmm.20181225.004DOI Listing
March 2019
3 Reads

Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer.

Cancer Chemother Pharmacol 2019 Apr 13. Epub 2019 Apr 13.

Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

Background/objective: Platinum-refractory or -resistant ovarian cancer (PRROC) is associated with poor prognosis and low response to further chemotherapy. We investigated predictors of effectiveness of following treatments for PRROC.

Patients And Methods: We included 380 patients diagnosed with stage I-IV ovarian, fallopian tube, or primary peritoneal cancer, who were treated at the National Cancer Center Hospital in Japan from January 2007 to December 2014 and recurred after initial treatment, who had a platinum-refractory or -resistant relapses and received chemotherapy, in this single-center, retrospective study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-03834-1DOI Listing
April 2019
2 Reads

Serous Adenocarcinoma of Fallopian Tubes: Histological and Immunohistochemical Aspects.

J Pathol Transl Med 2019 Apr 11. Epub 2019 Apr 11.

Department of Pathology, Sumy State University, Sumy, Ukraine.

Background: Although primary cancer of the fallopian tubes is a relatively rare type of tumor in female reproductive organs, its mortality is quite high. It is important to identify molecular and biological markers of this malignancy that determine its specific phenotype.

Materials And Methods: The study was carried out on samples received from 71 female patients with primary cancer of the fallopian tubes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4132/jptm.2019.03.21DOI Listing

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

Lancet Oncol 2019 Apr 1. Epub 2019 Apr 1.

Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St Joseph's Hospital, Phoenix, AZ, USA.

Background: Late-line treatment options for patients with ovarian cancer are few, with the proportion of patients achieving an overall response typically less than 10%, and median overall survival after third-line therapy of 5-9 months. In this study (QUADRA), we investigated the activity of niraparib monotherapy as the fourth or later line of therapy.

Methods: QUADRA was a multicentre, open-label, single-arm, phase 2 study that evaluated the safety and activity of niraparib in adult patients (≥18 years) with relapsed, high-grade serous (grade 2 or 3) epithelial ovarian, fallopian tube, or primary peritoneal cancer who had been treated with three or more previous chemotherapy regimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30029-4DOI Listing
April 2019
4 Reads

Sub-terahertz vibrational spectroscopy of ovarian cancer and normal control tissue for molecular diagnostic technology.

Cancer Biomark 2019 Mar 8. Epub 2019 Mar 8.

Vibratess LLC, Charlottesville, VA, 22902, USA.

We introduce here recently developed highly resolved Sub-Terahertz resonance spectroscopy of biological molecules and cells combined with molecular dynamics (MD) computational analysis as a new approach for optical visualization and quantification of the presence of microRNAs, particularly the mir-200 family, as potential biomarkers in samples from tissue of epithelial ovarian cancers for disease early detection, analysis, prognosis and treatment.METHOD: A set of samples for this study was prepared from anonymized archival formalin-fixed, paraffin-embedded ovarian epithelial tissue containing regions of invasive neoplastic cells from cases of high-histologic grade serous papillary ovarian carcinoma. Control samples were normal mucosa from fallopian tubes of patients with no known malignancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-182120DOI Listing
March 2019
2 Reads

ACOG Committee Opinion No. 774: Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention.

Authors:

Obstet Gynecol 2019 Apr;133(4):e279-e284

Opportunistic salpingectomy may offer obstetrician-gynecologists and other health care providers the opportunity to decrease the risk of ovarian cancer in their patients who are already undergoing pelvic surgery for benign disease. By performing salpingectomy when patients undergo an operation during which the fallopian tubes could be removed in addition to the primary surgical procedure (eg, hysterectomy), the risk of ovarian cancer is reduced. Although opportunistic salpingectomy offers the opportunity to significantly decrease the risk of ovarian cancer, it does not eliminate the risk of ovarian cancer entirely. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/AOG.0000000000003164DOI Listing
April 2019
4 Reads

ACOG Committee Opinion No. 774 Summary: Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention.

Authors:

Obstet Gynecol 2019 Apr;133(4):842-843

Opportunistic salpingectomy may offer obstetrician-gynecologists and other health care providers the opportunity to decrease the risk of ovarian cancer in their patients who are already undergoing pelvic surgery for benign disease. By performing salpingectomy when patients undergo an operation during which the fallopian tubes could be removed in addition to the primary surgical procedure (eg, hysterectomy), the risk of ovarian cancer is reduced. Although opportunistic salpingectomy offers the opportunity to significantly decrease the risk of ovarian cancer, it does not eliminate the risk of ovarian cancer entirely. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/AOG.0000000000003165DOI Listing
April 2019
2 Reads

PIPAC-OV3: A multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.

Pleura Peritoneum 2018 Sep 25;3(3):20180114. Epub 2018 Sep 25.

Charité University Medicine, Berlin, Germany.

Background: Recurrent, platin-resistant ovarian cancer (rPROC) has a poor survival. Even with the AURELIA trial, which is the best available treatment today, progression-free survival (PFS) is still only 6.7 months from the start of the second-line chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/pp-2018-0114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405004PMC
September 2018
1 Read

Primary peritoneal carcinosarcoma: A report of two cases.

Taiwan J Obstet Gynecol 2019 Mar;58(2):288-291

Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei, Taiwan. Electronic address:

Objective: Carcinosarcomas also known as malignant mixed mullerian tumors (MMMTs) contain both carcinomatous and sarcomatous elements. Most MMMTs are arising from female genital tract, including ovaries, uterus and fallopian tubes. Extragenital carcinosarcomas are extremely rare, with an estimation less than 40 cases so far. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tjog.2018.12.001DOI Listing
March 2019
1 Read

Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Short text of the French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa.

Eur J Obstet Gynecol Reprod Biol 2019 Mar 15. Epub 2019 Mar 15.

Service de Gynécologie-Obstétrique et Médecine de la Reproduction, Hôpital Tenon, 4 rue de La Chine, APHP, Institut Universitaire de Cancérologie Sorbonne Université, UMRS-938, France.

An MRI is recommended for an ovarian mass that is indeterminate on ultrasound. The ROMA score (combining CA125 and HE4) can also be calculated (Grade A). In presumed early-stage ovarian or tubal cancers, the following procedures should be performed: an omentectomy (at a minimum, infracolic), an appendectomy, multiple peritoneal biopsies, peritoneal cytology (grade C), and pelvic and para-aortic lymphadenectomies (Grade B) for all histologic types, except the expansile mucinous subtypes, for which lymphadenectomies can be omitted (grade C). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejogrb.2019.03.010DOI Listing
March 2019
3 Reads

Scope and Epidemiology of Gynecologic Cancers: An Overview.

Semin Oncol Nurs 2019 Apr 20;35(2):147-150. Epub 2019 Mar 20.

Interim Dean, Harris College of Nursing & Health Sciences, Associate Dean of Nursing & Professor, Texas Christian University, Ft Worth, TX.

Objective: To provide a current overview of the scope and epidemiology of gynecologic cancers.

Data Sources: A review of articles dated 2005-2018 from PubMed, as well as data from The Centers for Disease Control and Prevention, National Cervical Cancer Coalition, and the American Cancer Society.

Conclusion: Gynecologic cancers include any cancer that originates in a woman's reproductive system; cervical, ovarian, uterine, vaginal, vulvar, and fallopian tube (which is very rare), each named for the body part in which the cancer commences. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.soncn.2019.03.002DOI Listing
April 2019
1 Read

Chronic Chlamydia infection in human organoids increases stemness and promotes age-dependent CpG methylation.

Nat Commun 2019 03 18;10(1):1194. Epub 2019 Mar 18.

Department of Molecular Biology, Max Planck Institute for Infection Biology, Charitéplatz 1, 10117, Berlin, Germany.

Chronic infections of the fallopian tubes with Chlamydia trachomatis (Ctr) cause scarring and can lead to infertility. Here we use human fallopian tube organoids and genital Ctr serovars D, K and E for long-term in vitro analysis. The epithelial monolayer responds with active expulsion of the bacteria into the lumen and with compensatory cellular proliferation-demonstrating a role of epithelial homeostasis in the defense against this pathogen. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-019-09144-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423033PMC
March 2019
2 Reads

Hepatoid adenocarcinoma of fallopian tube: A case report and review of the literature.

Medicine (Baltimore) 2019 Mar;98(11):e14534

Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University.

Rationale: Hepatoid adenocarcinoma (HAC) of the fallopian tubes is a rare malignant tumor in the female reproductive system.

Patient Concerns: An 81-year-old Chinese woman presented with an elevated serum alpha-fetoprotein (AFP) level.

Diagnosis: Positron emission tomography-computed tomography (PET-CT) scan revealed a mass of approximately 47 × 27 mm located in the right adnexa. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014534DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426549PMC
March 2019
4 Reads

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.

Lancet Oncol 2019 Apr 14;20(4):570-580. Epub 2019 Mar 14.

Dana-Farber Cancer Institute, Boston, MA, USA.

Background: Based on preclinical work, we found that combination of poly (ADP-ribose) polymerase (PARP) inhibitors with drugs that inhibit the homologous recombination repair (HRR) pathway (such as PI3K inhibitors) might sensitise HRR-proficient epithelial ovarian cancers to PARP inhibitors. We aimed to assess the safety and identify the recommended phase 2 dose of the PARP inhibitor olaparib in combination with the PI3K inhibitor alpelisib in patients with epithelial ovarian cancer and in patients with breast cancer.

Methods: In this multicentre, open-label, phase 1b trial following a 3 + 3 dose-escalation design, we recruited patients aged 18 years or older with the following key eligibility criteria: confirmed diagnosis of either recurrent ovarian, fallopian tube, or primary peritoneal cancer of high-grade serous histology; confirmed diagnosis of either recurrent ovarian, fallopian tube, or primary peritoneal cancer of any histology with known germline BRCA mutations; confirmed diagnosis of recurrent breast cancer of triple-negative histology; or confirmed diagnosis of recurrent breast cancer of any histology with known germline BRCA mutations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30905-7DOI Listing
April 2019
3 Reads

A comparison of outcomes following total and selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian, fallopian tube and primary peritoneal cancer - A study by INDEPSO.

Eur J Surg Oncol 2019 Feb 23. Epub 2019 Feb 23.

Department of Surgical Oncology, Zydus Hospital, Ahmedabad, India. Electronic address:

Objectives: To compare clinical outcomes following total and selective peritonectomy performed during interval cytoreductive surgery (CRS) for stage IIIC/IVA serous epithelial ovarian cancer.

Methods: In this retrospective study, extent of peritonectomy was classified as total parietal peritonectomy (TPP) which comprised of removal of the entire parietal peritoneum and the greater and lesser omenta or selective parietal peritonectomy (SPP) that included 1/>1 of parietal peritonectomies performed to resect sites of residual disease. A comparison of patient and disease characteristics, morbidity, mortality and survival outcomes between the two groups was made. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejso.2019.02.031DOI Listing
February 2019
1 Read

Spontaneous resolution of dermatomyositis associated with fallopian-tube carcinoma following staging surgery: A case report.

Medicine (Baltimore) 2019 Mar;98(10):e14530

Department of Gynecologic Oncology, West China Second Hospital, Sichuan University.

Rationale: Paraneoplastic dermatomyositis (DM) is an inflammatory disease of the connective tissue caused by immunologic events in the presence of malignant tumors, which are typically related to ovarian, pancreatic, stomach, and colon cancer. Traditional treatment of paraneoplastic DM includes combination therapy for the underlying malignancy with systemic steroids.

Patient Concerns: A 41-year-old woman presented with facial erythema and myalgia of the extremities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014530DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417515PMC
March 2019
1 Read

Hydrosalpinx - Salpingostomy, salpingectomy or tubal occlusion.

Best Pract Res Clin Obstet Gynaecol 2019 Jan 29. Epub 2019 Jan 29.

Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK; Department of Obstetrics and Gynaecology, Princess Anne Hospital, Level F, Coxford Road, Southampton, SO16 5YA, UK.

Tubal factors account for approximately 25% of cases of infertility, and the most severe manifestation of tubal disease is hydrosalpinx, accounting for 10-30% of tubal diseases. Hydrosalpinx is a distension or dilatation of the fallopian tube in the presence of a distal tubal occlusion, and the most common cause is pelvic inflammatory disease. Women with hydrosalpinges have lower implantation and pregnancy rates in assisted reproductive technology (ART), due to a combination of mechanical and chemical factors thought to disrupt the endometrial environment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bpobgyn.2019.01.011DOI Listing
January 2019
2 Reads

GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer.

Future Sci OA 2019 Feb 10;5(2):FSO370. Epub 2019 Jan 10.

Department of Medical Oncology, Clinica Universitaria de Navarra, Madrid, Spain.

Response to polyadenosine diphosphate ribose polymerase () inhibitors in platinum-resistant ovarian cancer and in the absence of mutations is very low. Combining PARP inhibitors with other agents might overcome this lack of activity. Here we describe the rationale and design of GEICO1601-ROLANDO (resistant ovarian cancer treated with olaparib and pegylated liposomal doxorubin; NCT03161132). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4155/fsoa-2018-0107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391624PMC
February 2019
4 Reads

Can morphometric analysis of the fallopian tube fimbria predict the presence of uterine papillary serous carcinoma (UPSC)?

PLoS One 2019 28;14(2):e0211329. Epub 2019 Feb 28.

Department of Obstetrics and Gynecology, Rambam Health Care Campus, Haifa, Israel.

Uterine serous papillary carcinoma (UPSC) is an aggressive tumor, often diagnosed as a metastatic disease and characterized by a high recurrence rate and poor prognosis. UPSC represents a distinct subtype of endometrial cancer which is different in clinical and pathological behaviors from endometrioid endometrial carcinoma (EEC) and resembles more to serous ovarian carcinoma. Since tumors of serous papillary of the ovary are hypothesized to stem from cells of the fallopian tube's fimbria, we hypothesized that UPSC may also origin in the fallopian tubes. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211329PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394988PMC
February 2019
3 Reads

First-line treatment of women with advanced ovarian cancer: focus on bevacizumab.

Onco Targets Ther 2019 8;12:1095-1103. Epub 2019 Feb 8.

Department of Gynecological-Obstetrical and Urological Sciences, Sapienza University of Rome, Rome, Italy,

Ovarian cancer is the fifth most common cause of cancer death in women in Europe. Despite the progress, almost 70% of the patients relapse. The standard treatment is cytoreductive surgery followed by platinumtaxane chemotherapy; in patients with a disseminated disease, one option is neoadjuvant chemotherapy with delayed surgery (ie, interval debulking surgery). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S155425DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371937PMC
February 2019
2 Reads

Prophylactic salpingo-oophorectomy & surgical menopause for inherited risks of cancer: the need to identify biomarkers to assess the theoretical risk of premature coronary artery disease.

Womens Midlife Health 2018 27;4. Epub 2018 Apr 27.

1Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary, Health Research Innovation Centre, GB42, 3280 Hospital Dr NW, Calgary, AB T2N 4Z6 Canada.

Background: Some women with genetic risk of breast and/or ovarian cancer (e.g., BRCA1/2) opt to undergo prophylactic salpingo-oophorectomy (PSO, or surgical removal of the ovaries & fallopian tubes) in order to reduce their risk of cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40695-018-0037-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297996PMC
April 2018
1 Read

The Pathogenic Neisseria Use a Streamlined Set of Peptidoglycan Degradation Proteins for Peptidoglycan Remodeling, Recycling, and Toxic Fragment Release.

Front Microbiol 2019 31;10:73. Epub 2019 Jan 31.

Department of Medical Microbiology and Immunology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States.

and release peptidoglycan (PG) fragments from the cell as the bacteria grow. For these PG fragments are known to cause damage to human Fallopian tube tissue in organ culture that mimics the damage seen in patients with pelvic inflammatory disease. also releases pro-inflammatory PG fragments, but in smaller amounts than those from . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmicb.2019.00073DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365954PMC
January 2019
2 Reads

Concurrent isolated retroperitoneal HGSC and STIC defined by somatic mutation analysis: a case report.

Diagn Pathol 2019 Feb 11;14(1):17. Epub 2019 Feb 11.

Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Niigata, 951-8510, Japan.

Background: Retroperitoneal high-grade serous carcinoma (HGSC) is extremely rare and the origin remains unclear. We present a case of retroperitoneal HGSC and coexisting serous tubal intraepithelial carcinoma (STIC), which is considered as the main origin of ovarian HGSC. We reviewed the available literature and discussed about the origin of this rare disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13000-019-0795-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371506PMC
February 2019
7 Reads

Mechanism of trace acetamiprid-caused reproductive disorders in silkworm, Bombyx mori.

Pest Manag Sci 2019 Feb 10. Epub 2019 Feb 10.

School of Basic Medicine and Biological Sciences, Soochow University, Suzhou, China.

Background: Neonicotinoid insecticides are widely used in the prevention and control of pests in agriculture and forestry, but they can also affect the development of nontarget economic insects. In order to determine the effects of trace acetamiprid on the development of reproductive system of silkworm, we studied the gonad development and endogenous hormone metabolism in silkworms exposed to trace acetamiprid.

Result: The silkworm showed mild poisoning symptoms after being exposed to trace acetamiprid (0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ps.5373DOI Listing
February 2019
22 Reads

[Diagnostic value of imaging (ultrasonography, doppler, CT, MR, PET-CT) for the diagnosis of a suspicious ovarian mass and staging of ovarian, tubal or primary peritoneal cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].

Gynecol Obstet Fertil Senol 2019 02 25;47(2):123-133. Epub 2019 Jan 25.

Service de radiologie, université Paris Descartes Sorbonne Paris Cité, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 20, rue Leblanc, 75015 Paris, France; Université Paris Descartes Sorbonne Paris Cité, Inserm UMR-S970, Cardiovascular Research Center - PARCC, 56, rue Leblanc, 75015 Paris, France.

Transvaginal ultrasound is the first-line examination allowing characterizing 80 to 90% of adnexal masses (LP1). If performed by an expert, a subjective analysis is optimal. If performed by a non-expert, combining the use of Simple Rules with subjective analysis can achieve the diagnostic performance of an expert (LP1). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gofs.2018.12.012DOI Listing
February 2019
1 Read

Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Cancer Chemother Pharmacol 2019 Apr 24;83(4):717-726. Epub 2019 Jan 24.

TESARO, Inc, Waltham, MA, USA.

Purpose: Anticancer drugs may cause cardiovascular toxicities, including QT interval prolongation. Niraparib, a potent and selective once-daily oral poly (ADP-ribose) polymerase inhibitor, is approved as a maintenance therapy in platinum-sensitive recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer (EOC). Here, we present the effects of niraparib on cardiac repolarization, and the correlation between changes in baseline QT interval corrected by Fridericia's formula (ΔQTcF) and niraparib plasma concentrations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-03774-wDOI Listing
April 2019
3 Reads

Dose-dense cisplatin with gemcitabine for relapsed platinum-resistant ovarian cancer.

Int J Gynecol Cancer 2019 Jan 23. Epub 2019 Jan 23.

The Christie NHS Foundation Trust, Manchester, UK

Introduction: Standard of care treatment for women who develop relapsed ovarian cancer includes sequential platinum- and/or paclitaxel-based chemotherapy, with reducing disease-free intervals. Once platinum resistance develops, treatment options become limited and dose-dense regimens may be offered. We report the efficacy and safety of dose-dense cisplatin with gemcitabine chemotherapy for relapsed platinum-resistant ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2018-000067DOI Listing
January 2019

Ovarian cancer: screening and future directions.

Int J Gynecol Cancer 2019 Jan;29(1):195-200

Levine Cancer Institute, Charlotte, North Carolina, USA.

Ovarian cancer carries a lifetime risk of approximately 2% for women and is the leading cause of death from any gynecologic malignancy. Currently, no screening program for ovarian cancer exists for the general population in the UK. This review focuses on the evidence surrounding the efficacy of current markers and discusses future improvements in screening for this disease. Read More

View Article

Download full-text PDF

Source
http://ijgc.bmj.com/lookup/doi/10.1136/ijgc-2018-000016
Publisher Site
http://dx.doi.org/10.1136/ijgc-2018-000016DOI Listing
January 2019
18 Reads

Phase I study of intravenous oxaliplatin and intraperitoneal docetaxel in recurrent ovarian cancer.

Int J Gynecol Cancer 2019 Jan;29(1):147-152

University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

Introduction: Intraperitoneal (IP) chemotherapy improves survival in ovarian cancer but its use has been limited by toxicity with cisplatin-based regimens. The primary objective of this study was to define the maximum tolerated dose and dose-limiting toxicity of intravenous (IV) oxaliplatin and IP docetaxel in women with recurrent ovarian, fallopian tube or peritoneal cancer. Secondary objectives were response rate, time to progression, symptom interference with quality of life, and pharmacokinetics. Read More

View Article

Download full-text PDF

Source
http://ijgc.bmj.com/lookup/doi/10.1136/ijgc-2018-000055
Publisher Site
http://dx.doi.org/10.1136/ijgc-2018-000055DOI Listing
January 2019
13 Reads

Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.

Gynecol Oncol 2019 03 9;152(3):560-567. Epub 2019 Jan 9.

Dana-Farber Cancer Institute, Boston, MA, USA.

Objective: To analyze the safety and efficacy of niraparib in patients aged ≥70 years with recurrent ovarian cancer in the ENGOT-OV16/NOVA trial.

Methods: The trial enrolled 2 independent cohorts with histologically diagnosed recurrent ovarian, fallopian tube, or peritoneal cancer who responded to platinum rechallenge, on the basis of germline breast cancer susceptibility gene mutation (gBRCAmut) status. Patients were randomized 2:1 to receive niraparib (300 mg) or placebo once daily until disease progression. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258183147
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2018.12.009DOI Listing
March 2019
14 Reads

Xanthogranulomatous Oophoritis: A Rare Case Report.

Iran J Pathol 2018 12;13(3):372-376. Epub 2018 Sep 12.

Dept. of Pathology, Dayanand Medical College and Hospital, Ludhiana, India.

Xanthogranulomatous oophoritis is an uncommon, non-neoplastic, chronic process in which the affected organ is destroyed by massive cellular infiltration of foamy histiocytes admixed with multinucleated giant cells, plasma cells, fibroblasts, neutrophils, and foci of necrosis. The etiology of this entity is unknown, but it shares histopathological findings similar to those of xanthogranulomatous change occurring in various organs, including the gallbladder and kidney. The current case was a 20-year-old female presenting with a tubo-ovarian mass with suspicion of malignancy on clinicoradiological findings and final diagnosis of xanthogranulomatous oophritis established on histopathology. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322522PMC
September 2018
1 Read

TRPV4 is involved in levonorgestrel-induced reduction in oviduct ciliary beating.

J Pathol 2019 May 5;248(1):77-87. Epub 2019 Mar 5.

International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.

Previous studies revealed the increasing risk of tubal pregnancy following failure of levonorgestrel (LNG)-induced emergency contraception, which was attributed to the reduced ciliary motility in response to LNG. However, understanding of the mechanism of LNG-induced reduction in the ciliary beat frequency (CBF) is limited. The transient receptor potential vanilloid (TRPV) 4 channel is located widely in the female reproductive tract and generates an influx of Ca following its activation under normal physiological conditions, which regulates the CBF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.5233DOI Listing
May 2019
12 Reads
7.429 Impact Factor

Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer.

Int J Gynecol Cancer 2019 Jan 10. Epub 2019 Jan 10.

IRCCS National Cancer Institute "Fondazione G. Pascale" Naples, Napoli, Italy.

Background: There is mounting pre-clinical and clinical evidence that combinations of immunotherapy, specifically programed cell death-1 (PD-1) inhibition, with chemotherapy and anti-angiogenesis agents, such as bevacizumab, result in markedly improved outcomes across a variety of tumor types including endometrial cancer, renal cell cancer, and non-small cell lung cancer. IMagyn050/GOG 3015/ENGOT-OV39 is the first, randomized, phase III trial to evaluate the potential impact of this combination on both progression-free survival and overall survival in patients presenting with advanced epithelial ovarian cancer.

Primary Objective: The primary objective is to evaluate the efficacy of atezolizumab versus placebo in combination with paclitaxel + carboplatin + bevacizumab for front-line treatment of ovarian cancer among all patients and those with PD-L1+ tumors. Read More

View Article

Download full-text PDF

Source
http://ijgc.bmj.com/lookup/doi/10.1136/ijgc-2018-000071
Publisher Site
http://dx.doi.org/10.1136/ijgc-2018-000071DOI Listing
January 2019
21 Reads

Solitary CNS Metastasis on Initial Presentation of High Grade Serous Carcinoma of the Fallopian Tube.

Case Rep Obstet Gynecol 2018 5;2018:6930986. Epub 2018 Dec 5.

Department of Obstetrics and Gynecology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

A 68-year-old woman presented with a three-week history of confusion and anomic aphasia. Imaging of her head demonstrated a single large left frontal mass. Pathology revealed metastatic adenocarcinoma of Müllerian origin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/6930986DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304521PMC
December 2018
2 Reads

Intravasation Affects the Diagnostic Image Quality of Transvaginal 4-Dimensional Hysterosalpingo-Contrast Sonography With SonoVue.

J Ultrasound Med 2018 Dec 31. Epub 2018 Dec 31.

Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.

Objectives: We aim to retrospectively analyze the diagnostic image quality of transvaginal 4-dimensional hysterosalpingo-contrast sonography from infertile patients and determine the significant influencing factors.

Methods: A total of 445 patients visiting infertility clinics were included in the study, of which 167 were primary infertile and 278 were secondary infertile. The factors were recorded, including age; examination time; infertility type; history of pelvic inflammatory disease, pelvic surgery, intrauterine surgery, and ectopic pregnancy; endometrial thickness; uterine position; ovarian position; 2-dimensional image quality; intravasation quantity, position, and time; balloon volume; and the dosage of contrast agent or the sterile saline solution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jum.14914DOI Listing
December 2018
7 Reads

CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression.

Cancer Med 2019 Jan 18;8(1):351-362. Epub 2018 Dec 18.

Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Ji'nan, China.

TP53 mutation is considerably common in advanced high-grade serous ovarian cancer (HGSOC) and significantly associated with a poor prognosis. In this study, we investigated the role of Cyclin G1 (CCNG1), a target gene of wild-type TP53 (P53wt), in HGSOC and the possible regulatory mechanism between TP53 mutant (P53mt) and CCNG1 in the progression of HGSOC. High expression level of CCNG1 was found in 61. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.1812DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346265PMC
January 2019
2 Reads

Pathogenesis of and the Host Defense in Ascending Infections of Human Fallopian Tube.

Front Immunol 2018 21;9:2710. Epub 2018 Nov 21.

Department of Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, WI, United States.

is an obligate human pathogen that causes mucosal surface infections of male and female reproductive tracts, pharynx, rectum, and conjunctiva. Asymptomatic or unnoticed infections in the lower reproductive tract of women can lead to serious, long-term consequences if these infections ascend into the fallopian tube. The damage caused by gonococcal infection and the subsequent inflammatory response produce the condition known as pelvic inflammatory disease (PID). Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2018.02710
Publisher Site
http://dx.doi.org/10.3389/fimmu.2018.02710DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258741PMC
November 2018
13 Reads

Cytology of the fallopian tube: A screening model for high-grade serous carcinoma.

Cytojournal 2018 12;15:28. Epub 2018 Nov 12.

Address: Department of Medical and Surgical Gynecology, Mayo Clinic, Jacksonville, FL, USA.

Ovarian cancer is a heterogeneous disease having the highest gynecologic fatality in the United States with a 5-year survival rate of 46.5%. Poor overall prognosis is mostly attributed to inadequate screening tools, and the majority of diagnoses occur at late stages of the disease. Read More

View Article

Download full-text PDF

Source
http://www.cytojournal.com/text.asp?2018/15/1/28/245215
Publisher Site
http://dx.doi.org/10.4103/cytojournal.cytojournal_58_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243852PMC
November 2018
18 Reads

Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.

Gynecol Oncol 2019 02 3;152(2):243-250. Epub 2018 Dec 3.

Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Objective: To evaluate safety, tolerability, and antitumor activity of pembrolizumab monotherapy in patients with programmed death ligand 1 (PD-L1)-expressing advanced ovarian cancer enrolled in the multicohort, phase Ib KEYNOTE-028 trial.

Methods: Key inclusion criteria were age ≥18 years; advanced ovarian epithelial, fallopian tube, or primary peritoneal carcinoma; failure of previous therapy; and tumor PD-L1 positivity. Patients received pembrolizumab (10 mg/kg every 2 weeks) for ≤24 months or until disease progression/intolerable toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.11.017DOI Listing
February 2019
10 Reads

The fallopian tube, "precursor escape" and narrowing the knowledge gap to the origins of high-grade serous carcinoma.

Gynecol Oncol 2019 02 30;152(2):426-433. Epub 2018 Nov 30.

Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States of America. Electronic address:

Most ovarian carcinomas are high-grade serous carcinomas (HGSC) that contain TP53 mutations, present at advanced stage, and eventually become resistant to chemotherapy. The rapid evolution of this disease has been attributed to an origin in the distal fallopian tube, in the form of serous tubal intraepithelial carcinomas (STICs). This has led to a disease model where malignancy develops first in the tube and spreads to the peritoneum or regional lymph nodes. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258183145
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2018.11.033DOI Listing
February 2019
16 Reads

Genital Tract Pathology in Female Pet Guinea Pigs (Cavia porcellus): a Retrospective Study of 655 Post-mortem and 64 Biopsy Cases.

J Comp Pathol 2018 Nov 19;165:13-22. Epub 2018 Oct 19.

Institute of Veterinary Pathology, Freie Universität Berlin, Robert-von-Ostertagstrase 15, Germany. Electronic address:

Disorders of the female genital tract are among the most common disorders in pet guinea pigs (Cavia porcellus); however, knowledge of many aspects of these disorders is sparse, especially regarding their incidence and age distribution. Ovarian cysts, as the most common genital tract disorder in guinea pigs, have been investigated in detail; however, information on the nature of these cysts is inconsistent. The present study reviewed genital tract disorders occurring within 655 full post-mortem examinations of intact female pet guinea pigs and 64 female genital tract biopsies examined over a 22. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcpa.2018.09.001DOI Listing
November 2018
2 Reads

Back to the Future? The Fallopian Tube, Precursor Escape and a Dualistic Model of High-Grade Serous Carcinogenesis.

Cancers (Basel) 2018 Nov 28;10(12). Epub 2018 Nov 28.

Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.

Beginning with the discovery of the -associated ovarian cancer susceptibility genes and subsequent detailed examination of risk-reducing salpingo-oophorectomy (RRSO) specimens, a new paradigm of ovarian carcinogenesis has unfolded with attention to the distal fallopian tube. The primary focus has been an early cancer or neoplasm in the fallopian tube which is seen in virtually all incidentally discovered high-grade serous cancers in asymptomatic women. This high-frequency of tubal involvement in early serous neoplasm (usually in the form of serous tubal intraepithelial carcinoma-STIC) has galvanized attention to this organ as a primary source of this disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers10120468DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316244PMC
November 2018
2 Reads

Beyond prophylaxis: Extended risk of venous thromboembolism following primary debulking surgery for ovarian cancer.

Gynecol Oncol 2019 02 22;152(2):286-292. Epub 2018 Nov 22.

Department of Obstetrics and Gynecology, Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN, United States of America. Electronic address:

Objective: To determine the incidence and risk factors for venous thromboembolism (VTE) within six months after primary debulking surgery (PDS) for epithelial ovarian cancer (EOC).

Methods: In a historical cohort, we estimated the cumulative incidence of clinically diagnosed VTE within 6 months among consecutive women who underwent PDS for EOC at a single institution from 1/1/2003 to 12/31/2011. We evaluated perioperative variables as potential risk factors of VTE within 6 months during the postoperative period using univariate and multivariable Cox proportional hazards models. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258183142
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2018.11.021DOI Listing
February 2019
16 Reads

The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.

Gynecol Oncol 2019 02 22;152(2):228-234. Epub 2018 Nov 22.

Department of Obstetrics and Gynecology/Section of Gynecologic Oncology/Center for Integrated Science, University of Chicago, Chicago, IL 60637, United States of America. Electronic address:

Objective: It is unclear if the types of surgical procedures performed on long-term survivors (LTS) of high-grade serous ovarian carcinoma (HGSOC) contribute to prolonged survival. In this case-control study we review the surgical procedures performed on LTS and describe their individual longitudinal disease courses.

Methods: Women with FIGO stage III-IV high-grade serous cancer of the ovary, fallopian tube or peritoneum were selected from the University of Chicago ovarian cancer database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.11.007DOI Listing
February 2019
11 Reads

Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade.

Gynecol Oncol 2019 02 22;152(2):251-258. Epub 2018 Nov 22.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weil Cornell Medical College, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address:

Objective: Delayed responses observed with immune checkpoint blockade (ICB) present a challenge for patients with peritoneal malignancies, who risk early symptomatic disease progression requiring treatment discontinuation. While efforts are ongoing to define the biomarkers of response, it is equally important to identify patients at risk for early discontinuation. We sought to investigate the timing of disease progression in epithelial ovarian cancer (EOC) patients treated with ICB and to identify pre-treatment clinical parameters associated with early discontinuation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.11.025DOI Listing
February 2019
33 Reads

Current First-line Therapy for Ovarian Cancer: A Comprehensive Review.

Obstet Gynecol Surv 2018 Nov;73(11):650-657

Assistant Professor, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC.

Importance: Ovarian, fallopian tube, and primary peritoneal cancers constitute the deadliest gynecologic malignancies. After primary cytoreductive surgery, there are several standard first-line cytotoxic treatments for providers to consider. Newer molecular targeted therapies are becoming more common and may have a role as first-line therapy in the future. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/OGX.0000000000000613DOI Listing
November 2018
15 Reads